down arrow

Jiangsu Cowin Biotech Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005NM2
CNY
26.27
5.54 (26.72%)

Dec 05

SHG

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Jiangsu Cowin Biotech Co., Ltd.
Why is Jiangsu Cowin Biotech Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -39.85% and Operating profit at -230.41% over the last 5 years
2
With a growth in Net Profit of 57.27%, the company declared Very Positive results in Mar 25
  • NET PROFIT(HY) Higher at CNY -87.22 MM
  • RAW MATERIAL COST(Y) Fallen by -58.76% (YoY)
  • DEBTORS TURNOVER RATIO(HY) Highest at 2.31%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 19.90%, its profits have fallen by -32.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Jiangsu Cowin Biotech Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jiangsu Cowin Biotech Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Jiangsu Cowin Biotech Co., Ltd.
-100.0%
0.86
52.72%
China Shanghai Composite
15.19%
1.04
14.54%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-39.85%
EBIT Growth (5y)
-230.41%
EBIT to Interest (avg)
-37.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.13
Tax Ratio
3.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.10%
ROE (avg)
2.89%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.49
EV to EBIT
1.31
EV to EBITDA
1.71
EV to Capital Employed
-0.53
EV to Sales
-1.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-12.32%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
NET PROFIT(HY)

Higher at CNY -87.22 MM

RAW MATERIAL COST(Y)

Fallen by -58.76% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 2.31%

NET SALES(Q)

Highest at CNY 42.49 MM

PRE-TAX PROFIT(Q)

Highest at CNY -27.58 MM

-12What is not working for the Company
INTEREST(9M)

At CNY 0.95 MM has Grown at 16.28%

NET PROFIT(9M)

At CNY -134.3 MM has Grown at -28.69%

ROCE(HY)

Lowest at -9.83%

Here's what is working for Jiangsu Cowin Biotech Co., Ltd.
Net Sales
At CNY 42.49 MM has Grown at 50.37%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (CNY MM)

Net Profit
Higher at CNY -87.22 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Sales
Highest at CNY 42.49 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit
Highest at CNY -27.58 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Debtors Turnover Ratio
Highest at 2.31%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -58.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jiangsu Cowin Biotech Co., Ltd.
Interest
At CNY 0.59 MM has Grown at 47.9%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."